Granted Patent
B2
US 12,296,018 · App. 16/964,832 · Granted May 13, 2025
Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
Assignee:
Duke University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are albumin binding peptide drug (AlBiPeD) conjugates comprising a small molecule linked to an albumin binding domain (ABD) via a pH-sensitive linker and methods of purifying and using the same.
Claims (18)
1. A composition comprising:
an albumin binding domain (ABD) consisting of the amino acid sequence of SEQ ID NO:1;
a linker coupled to the ABD at the C terminus of the ABD, the linker consisting of the amino acid sequence of (CGG) z (SEQ ID NO:3), wherein z is selected from the group consisting of 1, 2, 3, and 4, wherein if there is more than one sequence of CGG, the amino acid sequence, wherein the N terminus cysteine of the linker is coupled to the C terminus ABD is repeated sequentially;
one or two chemotherapeutic molecules selected from the group consisting of doxorubicin, paclitaxel, and docetaxel;
wherein the one or two chemotherapeutic molecules are individually coupled to a cysteine thiol of the amino acid sequence of CGG through a 3,3′-N-[ε-maleimidocaproic acid] hydrazide moiety; and
wherein the composition has an aqueous solubility of up to 4 mg of molecule equivalent/mL.
2. The composition of claim 1 , wherein the molecule is doxorubicin.
3. A method of killing cancer cells comprising contacting cancer cells with an effective amount of the composition of claim 1 , wherein the cancer cells are colon cancer cells or pancreatic cancer cells.
4. A method of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of the composition of claim 1 , wherein the cancer is colon cancer or pancreatic cancer.
5. A method of purifying the composition of claim 1 , comprising
forming a conjugate comprising, an elastin-like polypeptide having a transition temperature (T t ) above 50° C.; and the composition of claim 1 , wherein the composition is conjugated to a first end of the elastin-like polypeptide by an amino acid sequence amenable to cleavage;
treating the conjugate with an enzyme, chemical, or combination thereof capable of cleaving the amino acid sequence amenable to cleavage; and
separating the composition from the elastin-like polypeptide.
6. The method of claim 5 , further comprising a destabilizing peptide conjugated to a second end to an elastin-like polypeptide, wherein the destabilizing peptide comprises SEQ ID NO: 5.
7. The method of claim 5 , wherein the amino acid sequence is amenable to cleavage by an enzyme, and wherein the enzyme is Sortase A.
8. The method of claim 5 , wherein the amino acid sequence amenable to cleavage comprises SEQ ID NO: 6.
9. The method of claim 5 , wherein the elastin-like polypeptide comprises the amino acid sequence of (VPGXaaG) p (SEQ ID NO: 4), wherein Xaa is any amino acid except proline and p is 1 to 500.
10. The method of claim 9 , wherein Xaa is alanine and p is 160.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 29, 2020
From: CHILKOTI, ASHUTOSH; YOUSEFPOUR, PARISA
To: DUKE UNIVERSITY
Reel/Frame 053347/0848 →
Continuity (2)
Provisional Application
62622249
· Jan 26, 2018
References Cited (400)
US 4415732A
· Caruthers et al.
· 1983
[cited by applicant]
US 4458066A
· Caruthers et al.
· 1984
[cited by applicant]
US 4500707A
· Caruthers et al.
· 1985
[cited by applicant]
US 4554101A
· Hopp
· 1985
[cited by applicant]
US 4668777A
· Caruthers et al.
· 1987
[cited by applicant]
US 4973679A
· Caruthers et al.
· 1990
[cited by applicant]
US 4976734A
· Urry et al.
· 1990
[cited by applicant]
US 5153319A
· Caruthers et al.
· 1992
[cited by applicant]
US 5250516A
· Urry
· 1993
[cited by applicant]
US 5278302A
· Caruthers et al.
· 1994
[cited by applicant]
US 5336256A
· Urry
· 1994
[cited by applicant]
US 5453496A
· Caruthers et al.
· 1995
[cited by applicant]
US 5534408A
· Green et al.
· 1996
[cited by applicant]
US 5578577A
· Ching et al.
· 1996
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5602244A
· Caruthers et al.
· 1997
[cited by applicant]
US 5676646A
· Hofmann et al.
· 1997
[cited by applicant]
US 5679647A
· Carson et al.
· 1997
[cited by applicant]
US 5702359A
· Hofmann et al.
· 1997
[cited by applicant]
US 5703055A
· Felgner et al.
· 1997
[cited by applicant]
US 5935776A
· Green et al.
· 1999
[cited by applicant]
US 6068650A
· Hofmann et al.
· 2000
[cited by applicant]
US 6096020A
· Hofmann
· 2000
[cited by applicant]
US 6120493A
· Hofmann
· 2000
[cited by applicant]
US 6150148A
· Nanda et al.
· 2000
[cited by applicant]
US 6181964B1
· Hofmann et al.
· 2001
[cited by applicant]
US 6192270B1
· Hofmann et al.
· 2001
[cited by applicant]
US 6207749B1
· Mayes et al.
· 2001
[cited by applicant]
US 6208893B1
· Hofmann
· 2001
[cited by applicant]
US 6216034B1
· Hofmann et al.
· 2001
[cited by applicant]
US 6233482B1
· Hofmann et al.
· 2001
[cited by applicant]
US 6241701B1
· Hofmann
· 2001
[cited by applicant]
US 6245515B1
· Vogelstein et al.
· 2001
[cited by applicant]
US 6296831B1
· Weller et al.
· 2001
[cited by applicant]
US 6302874B1
· Zhang et al.
· 2001
[cited by applicant]
US 6413587B1
· Hawker et al.
· 2002
[cited by applicant]
US 6512060B1
· Matyjaszewski et al.
· 2003
[cited by applicant]
US 6541580B1
· Matyjaszewski et al.
· 2003
[cited by applicant]
US 6623950B1
· Osten et al.
· 2003
[cited by applicant]
US 6649138B2
· Adams et al.
· 2003
[cited by applicant]
US 6660247B1
· Gutowska et al.
· 2003
[cited by applicant]
US 6841617B2
· Jeong et al.
· 2005
[cited by applicant]
US 6852834B2
· Chilkoti
· 2005
[cited by applicant]
US 6869588B2
· Weller et al.
· 2005
[cited by applicant]
US 7033571B2
· Gutowska et al.
· 2006
[cited by applicant]
US 7087244B2
· Jeong et al.
· 2006
[cited by applicant]
US 7300922B2
· Sullenger et al.
· 2007
[cited by applicant]
US 7429458B2
· Chilkoti
· 2008
[cited by applicant]
US 7531524B2
· Rusconi
· 2009
[cited by applicant]
US 7664545B2
· Westersten et al.
· 2010
[cited by applicant]
US 7674882B2
· Kaplan et al.
· 2010
[cited by applicant]
US 8129330B2
· Martinez et al.
· 2012
[cited by applicant]
US 8283125B2
· Cebolla Ramirez et al.
· 2012
[cited by applicant]
US 8470967B2
· Chilkoti et al.
· 2013
[cited by applicant]
US 8497356B2
· Chilkoti et al.
· 2013
[cited by applicant]
US 8506963B2
· Li et al.
· 2013
[cited by applicant]
US 8586347B2
· Lochhead et al.
· 2013
[cited by applicant]
US 8841414B1
· Raucher et al.
· 2014
[cited by applicant]
US 8912310B2
· Chilkoti et al.
· 2014
[cited by applicant]
US 8937153B2
· Abrahmsen
· 2015
[cited by examiner]
US 9127047B2
· Chilkoti
· 2015
[cited by applicant]
US 9132178B2
· Philip
· 2015
[cited by applicant]
US 9138743B2
· Yager et al.
· 2015
[cited by applicant]
US 9482664B2
· Chilkoti et al.
· 2016
[cited by applicant]
US 9592303B2
· Chilkoti et al.
· 2017
[cited by applicant]
US 9771396B2
· Chilkoti et al.
· 2017
[cited by applicant]
US 9804170B2
· Krishna et al.
· 2017
[cited by applicant]
US 9890420B2
· Chilkoti et al.
· 2018
[cited by applicant]
US 20020052443A1
· Greenwald et al.
· 2002
[cited by applicant]
US 20020146794A1
· Tomycz
· 2002
[cited by applicant]
US 20040053976A1
· Martinez et al.
· 2004
[cited by applicant]
US 20040101852A1
· Bennett et al.
· 2004
[cited by applicant]
US 20050255554A1
· Chilkoti
· 2005
[cited by applicant]
US 20070117173A1
· Levison et al.
· 2007
[cited by applicant]
US 20090098652A1
· Stupp et al.
· 2009
[cited by applicant]
US 20100015070A1
· Bollschweiler et al.
· 2010
[cited by applicant]
US 20110082283A1
· Dagher et al.
· 2011
[cited by applicant]
US 20110119778A1
· Liss
· 2011
[cited by applicant]
US 20110207673A1
· Chilkoti et al.
· 2011
[cited by applicant]
US 20110248698A1
· Kikuchi et al.
· 2011
[cited by applicant]
US 20120172298A1
· Andersen et al.
· 2012
[cited by applicant]
US 20130079280A1
· Baca et al.
· 2013
[cited by applicant]
US 20130172274A1
· Chilkoti
· 2013
[cited by applicant]
US 20130197359A1
· Park et al.
· 2013
[cited by applicant]
US 20140024600A1
· Chilkoti et al.
· 2014
[cited by applicant]
US 20160120952A1
· Chilkoti
· 2016
[cited by applicant]
US 20170369651A1
· Cheng et al.
· 2017
[cited by applicant]
US 20180135060A1
· Romero Ramos et al.
· 2018
[cited by applicant]
US 20180161772A1
· Rammohan et al.
· 2018
[cited by applicant]
US 20180231469A1
· Gibbons et al.
· 2018
[cited by applicant]
US 20180369399A1
· Hershfield et al.
· 2018
[cited by applicant]
US 20190016763A1
· Kitazawa et al.
· 2019
[cited by applicant]
US 20190204309A1
· Gibbs
· 2019
[cited by applicant]
US 20190285623A1
· Chilkoti et al.
· 2019
[cited by applicant]
US 20190292549A1
· Zhang et al.
· 2019
[cited by applicant]
US 20190345228A1
· Chilkoti et al.
· 2019
[cited by applicant]
US 20200163878A1
· Baumhof et al.
· 2020
[cited by applicant]
AU 2007265628B2
· 2012
[cited by applicant]
CA 2327325A1
· 1999
[cited by applicant]
CA 2423488A1
· 2002
[cited by applicant]
CN 102575229A
· 2012
[cited by applicant]
CN 104725628B
· 2018
[cited by applicant]
CN 112961065A
· 2021
[cited by applicant]
EP 1670315B1
· 2017
[cited by applicant]
EP 2664340B1
· 2020
[cited by applicant]
JP 2014156428A
· 2014
[cited by applicant]
JP 2014534265A
· 2014
[cited by applicant]
WO WO1991019813A1
· 1991
[cited by applicant]
WO WO2003040165A2
· 2002
[cited by applicant]
WO WO2004096124A2
· 2004
[cited by applicant]
WO WO2006004778A2
· 2006
[cited by applicant]
WO 2006110292A2
· 2006
[cited by applicant]
WO WO2007073486A2
· 2007
[cited by applicant]
WO WO2007108013A2
· 2007
[cited by applicant]
WO WO2007134245A2
· 2007
[cited by applicant]
WO 2008012543A1
· 2008
[cited by applicant]
WO 2008030968A2
· 2008
[cited by applicant]
WO WO2009067584A1
· 2009
[cited by applicant]
WO WO2010054699A1
· 2010
[cited by applicant]
WO WO2010057154A1
· 2010
[cited by applicant]
WO WO2010096422A1
· 2010
[cited by applicant]
WO 2011025572A1
· 2011
[cited by applicant]
WO WO2011123813A2
· 2011
[cited by applicant]
WO 2012156058A1
· 2012
[cited by applicant]
WO 2012162426A1
· 2012
[cited by applicant]
WO WO2013049234A2
· 2013
[cited by applicant]
WO WO2013065009A1
· 2013
[cited by applicant]
WO 2013106715A1
· 2013
[cited by applicant]
WO WO2014037373A1
· 2014
[cited by applicant]
WO WO2014194244A1
· 2014
[cited by applicant]
WO 2015011231A1
· 2015
[cited by applicant]
WO WO2015130846A2
· 2015
[cited by applicant]
WO 2016065300A1
· 2016
[cited by applicant]
WO WO2016065273A1
· 2016
[cited by applicant]
WO WO2016090103A1
· 2016
[cited by applicant]
WO WO2016154530A1
· 2016
[cited by applicant]
WO WO2017015132A1
· 2017
[cited by applicant]
WO WO2017024182A1
· 2017
[cited by applicant]
WO WO2017112825A2
· 2017
[cited by applicant]
WO WO2017112826A2
· 2017
[cited by applicant]
WO WO2017192449A1
· 2017
[cited by applicant]
WO WO2018115401A1
· 2018
[cited by applicant]
WO WO2018144854A1
· 2018
[cited by applicant]
WO 2019103744A1
· 2019
[cited by applicant]
WO WO2019147954A1
· 2019
[cited by applicant]
WO 2020037100A1
· 2020
[cited by applicant]
WO 2020037214A1
· 2020
[cited by applicant]
WO 2020051223A1
· 2020
[cited by applicant]
WO 2020160472A1
· 2020
[cited by applicant]
WO 2021178898A1
· 2021
[cited by applicant]
WO 2022016089A2
· 2022
[cited by applicant]
WO 2022178438A1
· 2022
[cited by applicant]
WO 2022066635A1
· 2023
[cited by applicant]
Alves AC, Magarkar A, Horta M, Lima JLFC, Bunker A, Nunes C, Reis S. Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies. Sci Rep. Jul. 24, 2017;7(1):6343 (Year: 2017…
[cited by examiner]
AACR, “AACR Cancer Progress Report 2016,” Clin Cancer Res, Oct. 2016, vol. 22, Issue 19, 143 pages.
[cited by applicant]
Aaron et al., “Elastin as a Random-Network Elastomer—a Mechanical and Optical Analysis of Single Elastin Fibers,” Biopolymers, 1981, 20(6):1247-1260.
[cited by applicant]
Abbruzzese et al., “A phase I clinical, plasma, and cellular pharmacology study of gemcitabine,” J. Clin. Oncol. 1991, 3, 491-498.
[cited by applicant]
Adams et al., “Safety and utilization of blood components as therapeutic delivery systems,” Curr Pharm Biotechnol, 2003, 4(5):275-82.
[cited by applicant]
Adams et al., “Sustained release of antibiotics from injectable and thermally responsive polypeptide depots,” J Biomed Mater Res B Appl Biomater, Jul. 2009, vol. 90B, Issue 1, pp. 67-74.
[cited by applicant]
Adamska et al., “Pancreatic ductal adenocarcinoma: Current and evolving therapies,” J Mol Sci, Jun. 2017, vol. 18, Issue 7, pp. 1338-1380.
[cited by applicant]
Adiseshaiah et al., “Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer,” Nat Rev Clin Oncol, Dec. 2016, vol. 13, Issue 12, pp. 750-765.
[cited by applicant]
Aladini et al., “Chemical Synthesis and Characterization of Elastin-Like Polypeptides (ELPs) With Variable Guest Residues,” J Pept Sci, May 2016, vol. 22, Issue 5, pp. 334-342.
[cited by applicant]
Alarcon et al., “Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level,” Diabetologia, 2006, 49(12):2920-292…
[cited by applicant]
Albanese et al., “The effect of nanoparticle size, shape, and surface chemistry on biological systems,” Annu. Rev. Biomed. Eng., Aug. 2012, vol. 14, pp. 1-16.
[cited by applicant]
Alconcel et al., “FDA-approved poly(ethylene glycol)-protein conjugate drugs,” Polym. Chem., vol. 2, Apr. 2011, Issue 7, pp. 1442-1448.
[cited by applicant]
Allen et al., “Liposomal drug delivery systems: from concept to clinical applications,” Adv Drug Deliv Rev, Elsevier, Jan. 2013, 65(1):36-48.
[cited by applicant]
Alley et al., “Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay,” Cancer Res., 1988, 48, 589-601.
[cited by applicant]
Aluri et al., “Elastin-like peptide amphiphiles Form nanofibers with tunable length,” Biomacromolecules, Sep. 2012, vol. 13, Issue 9, pp. 2645-2654.
[cited by applicant]
American Diabetes Association, Standards of medical care in diabetes—2018. Diabetes Care, Jan. 2018, vol. 41, Supplement 1, pp. S1-S159.
[cited by applicant]
Amiram et al., “A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection,” J. Control. Release, Nov. 2013, vol. 172, Issue, pp. 144-151.
[cited by applicant]
Amiram et al., “Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control,” Proc. Natl. Acad. Sci., Feb. 2013, vol. 110, Issue 8, pp. 2792-2797.
[cited by applicant]
Andersen et al., “Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain,” Journal of Biological Chemistry, Feb. 2011, vol. 286, Issue 7, pp. 5234-5241.
[cited by applicant]
Anselmo et al., “Nanoparticles in the clinic,” Bioeng Transl Med, Jun. 2016, 1(1):10-29.
[cited by applicant]
Antos et al., “Lipid Modification of Proteins through Sortase-Catalyzed Transpeptidation,” J. Am. Chem. Soc., Dec. 2008, vol. 130, Issue 48, pp. 16338-16343.
[cited by applicant]
Antos et al., “Site-Specific N- and C-Terminal Labeling of a Single Polypeptide Using Sortases of Different Specificity,” J. Am. Chem. Soc., Aug. 2009, vol. 131, Issue 31, pp. 10800-10801.
[cited by applicant]
Arami et al., “In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles,” Chem Soc Rev, Dec. 2015, 44(23):8576-8607.
[cited by applicant]
Arias et al., “Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system,” Biomacromolecules, Jan. 2011, vol. 12, Issue 1, pp. 97-104.
[cited by applicant]
Armstrong et al., “Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients,” Cancer, Jul. 2007, vol. 110, Issue 1, pp. 103-111.
[cited by applicant]
Armstrong et al., “The Hydrodynamic Radii of Macromolecules and Their Effect on Red Blood Cell Aggregation,” Biophys. J., 2004, 87, 4259-4270.
[cited by applicant]
Arner et al., “FGF21 attenuates lipolysis in human adipocytes—a possible link to improved insulin sensitivity,” FEBS Lett, May 2008, vol. 582, Issue 12, pp. 1725-1730.
[cited by applicant]
Arnida et al., “Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages,” Eur J Pharm Biopharm, Apr. 2011, vol. 77, Issue 3, pp. 417-423.
[cited by applicant]
Asai et al., “Protein polymer hydrogels by in situ, rapid and reversible self-gelation,” Biomaterials, Jul. 2012, vol. 33, Issue 21, pp. 5451-5458.
[cited by applicant]
Astete et al., “Synthesis and characterization of PLGA nanoparticles,” Journal of Biomaterials Science, Polymer Edition 2006, 17(3):247-289.
[cited by applicant]
Atun et al., “Expanding global access to radiotherapy,” Lancet Oncol, Sep. 2015, vol. 16, Issue 10, pp. 1153-1186.
[cited by applicant]
Averick et al., “ATRP under biologically relevant conditions: grafting from a protein,” ACS Macro. Lett., Jan. 2012, vol. 1, Issue 1, pp. 6-10.
[cited by applicant]
Averick et al., “Protein-polymer hybrids: conducting ARGET ATRP from a genetically encoded cleavable ATRP initiator,” Eur. Polym. J., Oct. 2013, vol. 49, Issue 10, pp. 2919-2924.
[cited by applicant]
Awai et al., “Studies of the metabolism of I-131-labeled human transferrin,” J. Lab. Clin. Med. 61, 1963, 363-396.
[cited by applicant]
Awasthi et al., “Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer,” Carcinogenesis, Oct. 2013, vol. 34, Issue 10, pp. 2361-2369.
[cited by applicant]
Awasthi et al., “Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer,” Journal of Clinical Oncology, 2012, 30, 170.
[cited by applicant]
Axup et al., “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids,” Proc Natl Acad Sci USA, Feb. 2012, vol. 109, Issue 40, pp. 16101-16106.
[cited by applicant]
Azhdarinia et al., “Regional radiochemotherapy using in situ hydrogel,” Pharm Res., 2005, 22, 776-783.
[cited by applicant]
Babu, “The contribution of intrinsically disordered regions to protein function, cellular complexity, and human disease,” Biochem Soc Trans, Oct. 2016, 44(5):1185-1200.
[cited by applicant]
Bache et al., “Investigating the accuracy of microstereotactic-body-radiotherapy utilizing anatomically accurate 3D printed rodent-morphic dosimeters,” Medical Physics, Feb. 2015, vol. 42, Issue 2, pp. 846-855.
[cited by applicant]
Badi, “Non-linear PEG-based thermoresponsive polymer systems,” Progress in Polymer Science, Mar. 2017, vol. 66, pp. 54-79.
[cited by applicant]
Bae et al., “Targeted drug delivery to tumors: myths, reality and possibility,” J Control Release, Elsevier, Aug. 2011, 153(3):198-205.
[cited by applicant]
Baggio et al., “A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose…
[cited by applicant]
Baggio et al., “Biology of Incretins: GLP-1 and GIP,” Gastroenterology, May 2007, vol. 132, Issue 6, pp. 2131-2157.
[cited by applicant]
Bailey et al., “Genomic analyses identify molecular subtypes of pancreatic cancer,” Nature, Mar. 2016, vol. 531, Issue 7592, pp. 47-52.
[cited by applicant]
Balu et al., “An16-resilin: an advanced multi-stimuli-responsive resilin-mimetic protein polymer,” Acta Biomater, Nov. 2014, 10:4768-4777.
[cited by applicant]
Bamford et al., “The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website,” British Journal of Cancer, 2004, 91, 355-358.
[cited by applicant]
Banani et al., “Biomolecular condensates: organizers of cellular biochemistry,” Nat Rev Mol Cell Biol, May 2017, 18(5):285-298.
[cited by applicant]
Banerjee et al., “Nanoparticles in cancer chemotherapy,” Prog Mol Biol Transl Sci, Elsevier, Nov. 2011, 104:489-507.
[cited by applicant]
Banga et al., “Parenteral controlled delivery and parmacokinetics of therapeutic peptides and proteins,” (CRC Press, Boca Raton, FL, 2005).
[cited by applicant]
Banjade et al., “Phase transitions of multivalent proteins can promote clustering of membrane receptors,” Elife, Oct. 2014, 3:e04123.
[cited by applicant]
Bansal et al., “PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis,” J. Control. Release, Sep. 2011, vol. 154, Issue 3, pp. 233-240.
[cited by applicant]
Banskota et al., “Genetically encoded stealth nanoparticles of a zwitterionic polypeptide-paclitaxel conjugate have wider therapeutic window than Abraxane in multiple tumor models,” Nano Lett, Mar. 2020, 20(4):2396-2409.
[cited by applicant]
Barbuti et al., “Paclitaxel through the ages of anticancer therapy: Exploring its role in chemoresistance and radiation therapy,” Cancers, Dec. 2015, vol. 7, Issue 4, pp. 2360-2371.
[cited by applicant]
Barnett et al., “Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype,” Nat Rev Cancer, Feb. 2009, vol. 9, Issue 2, pp. 134-142.
[cited by applicant]
Barton et al., “Estimating the demand for radiotherapy form the evidence: A review of changes from 2003 to 2012,” Radiother Oncol, Jul. 2014, vol. 112, Issue 1, pp. 140-144.
[cited by applicant]
Baskar et al., “Cancer and Radiation Therapy: Current Advances and Future Directions,” Int. J. Med. Sci., Feb. 2012, vol. 9, Issue 3, pp. 193-199.
[cited by applicant]
Bates et al., “Block copolymer thermodynamics: theory and experiment,” Annu Rev. Phys. Chem., 1990, 41:525-57.
[cited by applicant]
Bedford et al., “WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: The proline glycine and methionine-rich motif,” PNAS, 1998, 95: 10602-10607.
[cited by applicant]
Beenken et al., “The FGF family: biology, pathophysiology and therapy,” Nat Rev Drug Discov, Mar. 2009, vol. 8, Issue 3, pp. 235-253.
[cited by applicant]
Begg et al., “Strategies to improve radiotherapy with targeted drugs,” Nat Rev Cancer, Apr. 2011, vol. 11, Issue 4, pp. 239-253.
[cited by applicant]
Bellucci et al., “A noncanonical function of sortase enables site-specific conjugation of small molecules to lysine residues in proteins,” Angew. Chem. Int. Ed. 54, Jan. 2015, vol. 54, Issue 2, pp. 441-445.
[cited by applicant]
Bellucci et al., “Three-in-One Chromatography-Free Purification, Tag Removal, and Site-Specific Modification of Recombinant Fusion Proteins Using Sortase A and Elastin-like Polypeptides,” Angewandte Chemie International…
[cited by applicant]
Bender et al., “Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine,” J. Med. Chem., Nov. 2009, vol. 52, Issue 22, pp. 6958-6961.
[cited by applicant]
Berisio et al., “Imino Acids and Collagen Triple Helix Stability: Characterization of Collagen-like Polypeptides Containing Hyp-Hyp-Gly Seqeucne Repeats,” JACS, 2004, 126: 11402-11403.
[cited by applicant]
Bernacki et al., “Length-dependent aggregation of uninterrupted polyalanine peptides,” Biochemistry, Sep. 2011, vol. 50, Issue 43, pp. 9200-9211.
[cited by applicant]
Berndt et al., “Synthetic lipidation of peptides and amino acids: Monolayer structure and properties,” J. Am. Chem. Soc., 1995, 117, 9515-9522.
[cited by applicant]
Bessa et al., “Thermoresponsive self-assembled elastin-based nanoparticles for delivery of BMPs,” Journal of Controlled Release, Mar. 2010, vol. 142, Issue 3, pp. 312-318.
[cited by applicant]
Best, “Computational and theoretical advances in studies of intrinsically disordered proteins,” Curr Opin Struct Biol, Feb. 2017, 42:147-154.
[cited by applicant]
Bhattacharyya et al., “A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models,” Nat. Commun., Aug. 2015, Issue 6, Article 7939, 30 pages.
[cited by applicant]
Bhattacharyya et al., “Encapsulating a Hydrophilic Chemotherapeutic into Rod-Like Nanoparticles of a Genetically Encoded Asymmetric Triblock Polypeptide Improves its Efficacy,” Advanced functional materials, Mar. 2017, …
[cited by applicant]
Bidwell et al., “Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin,” Biochemical Pharmacology, Mar. 2007, vol. 73, Issue 5, pp. 620-631.
[cited by applicant]
Binz et al., “Engineering novel binding proteins from nonimmunoglobulin domains,” Nat Biotechnol, 2005, 23(10):1257-68.
[cited by applicant]
Blanco et al., “Principles of nanoparticle design for overcoming biological barriers to drug delivery,” Nat Biotechnol, Sep. 2015, 33(9):941-51.
[cited by applicant]
Blasko et al., “Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes,” Seminars in Radiation Oncology, 2002, 12, 81-94.
[cited by applicant]
Blasko et al., “The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma,” Radiother Oncol, 2000, 57, 273-278.
[cited by applicant]
Blasko et al., “Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance,” Endocurietherapy/Hyperthermia Oncology, 1987, 3, 131-139.
[cited by applicant]
Bley et al., “Microtubule stabilising agents and ionising radiation: Multiple exploitable mechanisms for combined treatment,” Eur J Cancer, Jan. 2013, vol. 49, Issue 1, pp. 245-253.
[cited by applicant]
Bobo et al., “Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date.” Pharmaceutical research, Oct. 2016, vol. 33, Issue 10, pp. 2373-2387.
[cited by applicant]
Bocci et al., “The pharmacological bases of the antiangiogenic activity of paclitaxel,” Angiogenesis, Jul. 2013, vol. 16, Issue 3, pp. 481-492.
[cited by applicant]
Bochicchio et al., “Investigating by CD the molecular mechanism of elasticity of elastomeric proteins,” Chirality, Sep. 2008, vol. 20, Issue 9, pp. 985-994.
[cited by applicant]
Boekhorst et al., “Genome-wide detection and analysis of cell wall-bound proteins with LPxTG-like sorting motifs,” J. Bacteriol. 187, 2005, 4928-4934.
[cited by applicant]
Boeynaems et al., “Protein Phase Separation: A New Phase in Cell Biology,” Trends Cell Biol, Jun. 2018, 28(6):420-435.
[cited by applicant]
Boldt, “Use of albumin: an update,” Br J. Anaesth., Mar. 2010, vol. 104, Issue 3, pp. 276-284.
[cited by applicant]
Bond, “Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus,” Proc. (Bayl. Univ. Med. Cent.), Jul. 2006, vol. 19, Issue 3, pp. 281-284.
[cited by applicant]
Bontempo et al., “Streptavidin as a macroinitiator for polymerization: in situ protein-polymer conjugate formation,” J. Am. Chem. Soc., 2005, 6508-6509.
[cited by applicant]
Borst et al., “The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance,” Structure, Nov. 2017, 25(11):1732-1739.e5.
[cited by applicant]
Bowditch et al., “Identification of a novel integrin binding site in fibronectin. Differential utilization by β3 integrins,” Journal of Biological Chemistry, 1994, 269(14):10856-10863.
[cited by applicant]
Boyer et al., “Well-Defined Protein-Polymer Conjugates via in Situ RAFT Polymerization,” J. Am. Chem. Soc., Jun. 2007, vol. 129, Issue 22, pp. 7145-7154.
[cited by applicant]
Branco et al., “Self-assembling materials for therapeutic delivery,” Acta Biomaterialia, Mar. 2009, vol. 5, Issue 3, pp. 817-831.
[cited by applicant]
Brangwynne et al., “Polymer physics of intracellular phase transitions,” Nature Physics, Nov. 2015, 11(11):899-904.
[cited by applicant]
Brannon-Peppas et al., “Nanoparticle and targeted systems for cancer therapy,” Advanced Drug Delivery Reviews, Elsevier, Sep. 2012, 64(11):206-212.
[cited by applicant]
Broome et al., “Expanding the utility of beta-galactosidase complementation: piece by piece,” Mol Pharm, ACS Publications, Feb. 2010, 7(1):60-74.
[cited by applicant]
Broyer et al., “Emerging synthetic approaches for protein-polymer conjugations,” Chem. Commun., Feb. 2011, vol. 47, Issue 8, pp. 2212-2226.
[cited by applicant]
Brusa et al., “Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs,” Anticancer Res., Jan. 2007, vol. 27, Issue 1A, pp. 195-199.
[cited by applicant]
Burchard, “Light Scattering Techniques,” Physical techniques for the study of food biopolymers, 1994, 151-213.
[cited by applicant]
Burke et al., “Multimodal nanoparticle imaging agents: design and applications,” Philos Trans A Math Phys Eng Sci, Nov. 2017, 375:20170261.
[cited by applicant]
Burnouf, “Modern plasma fractionation,” Transfus. Med. Rev., Apr. 2007, vol. 21, Issue 2, pp. 101-117.
[cited by applicant]
Buteau et al., “Glucagon-like peptide-1 prevents beta cell glucolipotoxicity,” Diabetologia, 2004, 47(5):806-815.
[cited by applicant]
Butler et al., “β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes,” Diabetes, 2003, 52(1):102-110.
[cited by applicant]
Cabral et al., “Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size,” Nature Nanotechnology, Oct. 2011, vol. 6, Issue 12, pp. 815-823.
[cited by applicant]
Cabrera et al., “Automated, High-Throughput Assays for Evaluation of Human Pancreatic Islet Function,” Cell Transplant, First published Nov. 2007, vol. 16, Issue 10, pp. 1039-1048.
[cited by applicant]
Cabrera et al., “Glutamate Is a Positive Autocrine Signal for Glucagon Release,” Cell Metab, Jun. 2008, vol. 7, Issue 6, pp. 545-554.
[cited by applicant]
Cai et al., “Long-acting preparations of exenatide,” Drug Des. Devel. Ther., Sep. 2013, vol. 7, pp. 963-970.
[cited by applicant]
Caliceti et al., “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates,” Adv. Drug Deliv. Rev, 2003, 55, 1261-1277.
[cited by applicant]
Callahan et al., “Triple stimulus-responsive polypeptide nanoparticles that enhance intratumoral spatial distribution,” Nano Letters, Mar. 2012, vol. 12, Issue 4, pp. 2165-2170.
[cited by applicant]
Camilloni et al., “Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts,” Biochemistry, Feb. 2012, vol. 51, Issue 11, pp. 2224-2231.
[cited by applicant]
Campbell et al., “Pegylated peptides V. Carboxy-terminal PEGlyted analogs of growth hormone- releasing factor (GRF) display enhanced duration of biological activity in vivo,” J. Peptide Res., 1997, 49:527-537.
[cited by applicant]
Cao et al., “Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography,” Int J Radiation Oncol Biol Phys, Feb. 2014, vol…
[cited by applicant]
Cardenes et al., “Locally advanced pancreatic cancer: Current therapeutic approach,” The Oncologist, Jun. 2006, vol. 11, Issue 6, pp. 612-623.
[cited by applicant]
Carreiras et al., “Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma,” Gynecol Oncol, 1996, 62(2):260-7.
[cited by applicant]
Carrico et al., “Introducing genetically encoded aldehydes into proteins,” Nat Chem Biol, Jun. 2007, vol. 3, Issue 6, pp. 321-322.
[cited by applicant]
Cataldo et al., “Radiation-induced crosslinking of collagen gelatin into a stable hydrogel,” Journal of Radioanalytical and Nuclear Chemistry, Sep. 2008, vol. 275, Issue 1, pp. 125-131.
[cited by applicant]
Centers for Disease Control and Prevention, “National Diabetes Statistics Report, 2017,” Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017. Reviewed: Feb. 24, 2018.
[cited by applicant]
Ceska et al., “A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Optimal conditions,” Clinica Chimica Acta, 1969, 26, 437-444.
[cited by applicant]
Chakrabartty et al., “Stability of α-Helices,” Adv Protein Chem, 1995, 46, 141-176.
[cited by applicant]
Champion et al., “Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers,” J Control Release, Elsevier, Aug. 2007, 121(1-2):3-9.
[cited by applicant]
Champion et al., “Role of particle size in phagocytosis of polymeric microspheres,” Pharm Res, Srpinger, Mar. 2008, 25(8):1815-21.
[cited by applicant]
Champion et al., “Role of target geometry in phagocytosis,” Proc Natl Acad Sci U S A, The National Academy of Sciences of the USA, Mar. 2006, 103(13):4930-4.
[cited by applicant]
Champion et al., “Shape induced inhibition of phagocytosis of polymer particles,” Pharm Res, Springer, Jan. 2009, 26(1):244-9.
[cited by applicant]
Chang et al., “Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition,” Int. J. Cancer, Jul. 2013, vol. 133, Issue 1, pp. 225-235.
[cited by applicant]
Chatterjee et al., “Type 2 diabetes,” The Lancet, Jun. 2017, vol. 389, Issue 10085, pp. 2239-2251.
[cited by applicant]
Chaudhury et al., “The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan,” J Exp Med, 2003, 197(3): p. 315-322.
[cited by applicant]
Chen et al., “Anisotropic hydrogels fabricated with directional freezing and radiation-induced polymerization and crosslinking method,” Materials Letters, Dec. 2012, vol. 89, pp. 104-107.
[cited by applicant]
Chen et al., “Anti-hypervariable region antibody induced by a defined peptide: An approach for studying the structural correlates of idiotypes,” PNAS, 1984, 81:1784-1788.
[cited by applicant]
Chen et al., “Bioinspired Modular Synthesis of Elastin-Mimic Polymers to Probe the Mechanism of Elastin Elasticity,” J. Am. Chem. Soc., Mar. 2010, vol. 132, Issue 13, pp. 4577-4579.
[cited by applicant]
Chen et al., “Rheology of Soft Materials,” Annual Review of Condensed Matter Physics, May 2010, vol. 1, pp. 301-322.
[cited by applicant]
Chen et al., “Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase,” Nat Methods, 2005, 2(2):99-104.
[cited by applicant]
Chen et al., “The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation,” Biomaterials, Nov. 2013, vol. 34, Issue 34, pp. 8776-8785.
[cited by applicant]
Chen, “Small-molecule delivery by nanoparticles for anticancer therapy,” Trends Mol Med, Cell Press, Dec. 2010, 16(12):594-602.
[cited by applicant]
Chilkoti et al., “Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery,” Advance Drug Delivery Reviews, 2002, 54:1093-1111.
[cited by applicant]
Chilkoti et al., “Stimulus responsive elastin biopolymers: applications in medicine and biotechnology,” Curr Opin Chem Biol, Dec. 2006, vol. 10, Issue 6, pp. 652-657.
[cited by applicant]
Chilkoti et al., “Targeted drug delivery by thermally responsive polymers,” Advanced Drug Delivery Reviews, 2002, 54:613-630.
[cited by applicant]
Chithrani et al., “Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells,” Nano Lett, Apr. 2006, vol. 6, Issue 4, pp. 662-668.
[cited by applicant]
Chithrani et al., “Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes,” Nano letters, ACS Publications, Jun. 2007, 7(6):1542-1550.
[cited by applicant]
Chitkara et al., “Self-Assembling, Amphiphilic Polymer—Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma,” Bioconjug. Chem., Jun. 2013, vol. 24, Issue 7, pp. 1161-1173.
[cited by applicant]
Cho et al., “Effects of hofmeister anions on the phase transition temperature of elastin-like polypeptides,” J. Phys. Chem. B., Nov. 2008, vol. 112, Issue 44, pp. 13765-13771.
[cited by applicant]
Cho et al., “Hydrogen bonding of β-turn structure is stabilized in D(2)O,” J Am Chem Soc, Oct. 2009, vol. 131, Issue 42, pp. 15188-15193.
[cited by applicant]
Cho et al., “Therapeutic nanoparticles for drug delivery in cancer,” Clin. Cancer Res., Mar. 2008, vol. 14, Issue 5, pp. 1310-1316.
[cited by applicant]
Chockalingam et al., “Design and application of stimulus-responsive peptide systems,” Protein Engineering, Design & Selection, Apr. 2007, 20(4):155-161.
[cited by applicant]
Choi et al., “Renal Clearance of Nanoparticles,” Nature biotechnology, Oct. 2007, vol. 25, Issue 10, pp. 1165-1170.
[cited by applicant]
Chow et al., “Peptide-based biopolymers in biomedicine and biotechnology,” Mater. Sci. Eng. R Reports, Jan. 2008, vol. 62, Issue 4, pp. 125-155.
[cited by applicant]
Chow et al., “Ultra-High Expression of a Thermally Responsive Recombinant Fusion Protein in
[cited by applicant]
Choy et al., “Investigation of taxol as a potential radiation sensitizer,” Cancer, 1993, 71, 3774-3778.
[cited by applicant]
Christensen et al., “Fusion order controls expression level and activity of elastin-like polypeptide fusion proteins,” Protein Science, Jul. 2009, vol. 18, Issue 7, pp. 1377-1387.
[cited by applicant]
Christensen et al., “Predicting Transition Temperatures of Elastin-Like Polypeptide Fusion Proteins,” Biomacromolecules, Mar. 2013, vol. 14, Issue 5, pp. 1514-1519.
[cited by applicant]
Cid-Arregui et al., “Perspectives in the treatment of pancreatic adenocarcinoma,” World Journal of Gastroenterology, Aug. 2015, vol. 21, Issue 31, pp. 9297-9316.
[cited by applicant]
Ciezki et al., “Brachytherapy or surgery? A composite view,” Oncology, Oct. 2009, vol. 23, Issue 11, pp. 960-964.
[cited by applicant]
Cima, “AVMA Guidelines for the Euthanasia of Animal: 2013 Edition,” Journal of the American Veterinary Medical Association, Jan. 2013, vol. 242, 102 pages.
[cited by applicant]
Cirulis et al., “Viscoelastic properties and gelation of an elastin-like polypeptide,” Journal of Rheology, Sep. 2009, vol. 53, Issue 5, pp. 1215-1228.
[cited by applicant]
Clarke et al., “Tropoelastin massively associates during coacervation to form quantized protein spheres,” Biochemistry, Jul. 2006, vol. 45, Issue 33, pp. 9989-9996.
[cited by applicant]
Clavéet al., “Amylase, lipase, pancreatic isoamylase, and phospholipase A in diagnosis of acute pancreatitis,” Clinical Chemistry, 1995, 41, 1129-1134.
[cited by applicant]
Coin et al., “Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences,” Nat. Protoc., Dec. 2007, vol. 2, Issue 12, 3247-3256.
[cited by applicant]
Colomb et al., “Radiation-Convertible Polymers from Norbornenyl Derivatives. Crosslinking with Ionizing Radiation,” Journal of Applied Polymer Science, 1970, 14, 1659-1670.
[cited by applicant]
Conner et al., “Regulated portals of entry into the cell,” Nature, 2003, 422(6927):37-44.
[cited by applicant]
Conrad et al., “ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock,” Plant Biotechnology Journal, Jan. 2011, vol. 9, Issue 1, pp. 22-31.
[cited by applicant]
Coskun et al., “Fibroblast Growth Factor 21 Corrects Obesity in Mice,” Endocrinology, Dec. 2008, vol. 149, Issue 12, pp. 6018-6027.
[cited by applicant]
Costa et al., “Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug,” Nano letters, Dec. 2018, 19(1):247-254.
[cited by applicant]
Craik et al., “The future of peptide-based drugs,” Chemical biology & drug design 81, Dec. 2013, vol. 81, Issue 1, pp. 136-147.
[cited by applicant]
Cui et al., “Amino acid sequence in constitutionally isomeric tetrapeptide amphiphiles dictates architecture of one-dimensional nanostructures,” J. Am. Chem. Soc., Aug. 2014, vol. 136, Issue 35, 12461-12468.
[cited by applicant]
Cui et al., “Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials,” Biopolymers, Jan. 2010, vol. 94, Issue 1, pp. 1-18.
[cited by applicant]
Dai et al., “Versatile biomanufacturing through stimulus-responsive cell—material feedback,” Nature chemical biology, Sep. 2019, 15(10):1017-1024.
[cited by applicant]
Dalhaimer et al., “Single Molecule Visualization of Stable, Stiffness-Tunable, Flow-Conforming Worm Micelles,” Macromolecules, 2003, 36(18):6873-6877.
[cited by applicant]
Dalla Poza et al., “Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity,” Biochim. Biophys. Acta, May 2013, vol. 1828, Issue 5, pp…
[cited by applicant]
Darzynkiewicz et al., “DNA content measurement for DNA ploidy and cell cycle analysis,” Current Protocols in Cytometry, 2001, 7.5.1-7.5.24.
[cited by applicant]